Articles related to CARDIOVASCULAR EVENTS
Aspirin Use to Prevent Cardiovascular Disease
CVD is the leading cause of death in the US, accounting for more than one in four deaths. Following a systematic review, the US Preventive Services Task Force has provided an update on the effectiveness of aspirin to reduce the risk of CVD events.
Cardiology May 3rd 2022
Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease
A study in the Annals of Internal Medicine looked at the association between cardiovascular outcomes and the coprescription of nitrates with PDE5 inhibitors in more than 42,000 men over a 10-year period. Two composite outcomes were measured: 1) cardiac arrest, shock, myocardial infarction, ischemic stroke, or acute coronary arteriography; and 2) syncope, angina pectoris, or drug-related adverse event. The authors found no statistically significant increase in measured cardiovascular AEs.
Cardiology April 27th 2022
Meta-Analysis Questions Strength of Ties Between Statin-Induced LDL Lowering, CV Outcomes
A meta-analysis published in JAMA Internal Medicine has concluded that the link between statin-induced LDL lowering and reduction of CV outcomes may not be as robust as previously assumed. According to the researchers, the absolute risk reduction associated with statin use for all-cause mortality was 0.8% (95% CI, 0.4-1.2), whereas for MI it was 1.3% (95% CI, 0.9-1.7) and for stroke it was 0.4% (95% CI, 0.2-0.6). Absolute risk reduction figures were slightly higher for secondary prevention than for primary prevention.
Cardiology March 22nd 2022
Sleep Academy Warns Lawmakers About Health Risks of Permanent Daylight-Saving Time
The American Academy of Sleep Medicine (AASM) is taking issue with the US Senate’s recently passed legislation that will make daylight saving time (DST) permanent starting in 2023. AASM cautions that this permanent change would lead to health risks that include adverse cardiovascular events, mood disorders, and motor vehicle crashes. The group advocates for establishing permanent standard time instead.
Cardiology March 22nd 2022
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients with Advanced RCC: Data from the Phase III JAVELIN Renal 101 Trial
Both immune checkpoint inhibitors (ICIs) and VEGF receptor inhibitors are approved for advanced renal cell carcinoma (RCC) treatment and can cause cardiovascular events (CVs). This randomized study of avelumab plus axitinib vs. sunitinib used prospective monitoring of LVEF and serum cardiac biomarkers to assess for the development of major adverse CV events. The results indicate patients with high baseline troponin T levels and who receive combination ICI and VEGF receptor inhibitor therapy should be monitored closely for adverse cardiac events.
Cardiology March 15th 2022